EICHORPublic-registry site landscape for NCT03653247, “A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease”, a Sickle Cell Disease study sponsored by Sangamo Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03653247 (registry record) |
| Study title | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease |
| Official title | A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease |
| Sponsor | Sangamo Therapeutics |
| Condition(s) | Sickle Cell Disease |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 5 |
| Intervention(s) | Plerixafor, Busulfan |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03653247.
Eichor generates a preliminary site-risk snapshot for NCT03653247 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
